| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neisseria gonorrhoeae | 100 | 2025 | 202 | 14.570 |
Why?
|
| Gonorrhea | 70 | 2025 | 160 | 11.630 |
Why?
|
| Lipopolysaccharides | 45 | 2025 | 616 | 5.040 |
Why?
|
| Bacterial Vaccines | 15 | 2023 | 80 | 2.890 |
Why?
|
| Anti-Bacterial Agents | 15 | 2025 | 800 | 2.880 |
Why?
|
| Complement System Proteins | 18 | 2022 | 109 | 2.730 |
Why?
|
| Complement Factor H | 18 | 2020 | 118 | 2.590 |
Why?
|
| Antibodies, Bacterial | 32 | 2023 | 182 | 2.470 |
Why?
|
| Chlamydia Infections | 15 | 2022 | 79 | 1.890 |
Why?
|
| Antigens, Bacterial | 28 | 2023 | 198 | 1.630 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 4 | 2025 | 59 | 1.520 |
Why?
|
| Spiro Compounds | 4 | 2025 | 12 | 1.420 |
Why?
|
| Blood Bactericidal Activity | 25 | 2011 | 61 | 1.410 |
Why?
|
| N-Acetylneuraminic Acid | 7 | 2025 | 48 | 1.390 |
Why?
|
| Epitopes | 19 | 2021 | 292 | 1.340 |
Why?
|
| Porins | 16 | 2019 | 63 | 1.330 |
Why?
|
| Chlamydia trachomatis | 17 | 2022 | 60 | 1.320 |
Why?
|
| Bacterial Outer Membrane Proteins | 20 | 2019 | 125 | 1.320 |
Why?
|
| Syphilis | 2 | 2020 | 25 | 1.250 |
Why?
|
| Immunoglobulin Fc Fragments | 6 | 2020 | 48 | 1.220 |
Why?
|
| Sialic Acids | 9 | 2020 | 33 | 1.190 |
Why?
|
| Bacterial Proteins | 12 | 2023 | 741 | 1.180 |
Why?
|
| Sexually Transmitted Diseases | 6 | 2025 | 95 | 1.180 |
Why?
|
| Complement Activation | 8 | 2021 | 50 | 1.130 |
Why?
|
| Urethritis | 7 | 2020 | 8 | 1.080 |
Why?
|
| Complement C4b-Binding Protein | 8 | 2019 | 28 | 1.040 |
Why?
|
| Neisseria meningitidis | 10 | 2019 | 76 | 1.020 |
Why?
|
| Immunoglobulin G | 21 | 2021 | 463 | 0.970 |
Why?
|
| Drug Resistance, Bacterial | 6 | 2022 | 95 | 0.970 |
Why?
|
| Barbiturates | 4 | 2025 | 6 | 0.920 |
Why?
|
| Humans | 137 | 2025 | 64726 | 0.890 |
Why?
|
| Antibodies, Monoclonal | 17 | 2021 | 876 | 0.820 |
Why?
|
| Animals | 45 | 2025 | 21248 | 0.820 |
Why?
|
| Biological Products | 1 | 2025 | 91 | 0.810 |
Why?
|
| Epidemics | 2 | 2020 | 26 | 0.790 |
Why?
|
| Ceftriaxone | 4 | 2022 | 19 | 0.780 |
Why?
|
| Disease Models, Animal | 10 | 2023 | 2256 | 0.770 |
Why?
|
| Drug Resistance, Multiple | 2 | 2020 | 28 | 0.770 |
Why?
|
| Heptoses | 3 | 2018 | 7 | 0.760 |
Why?
|
| Vagina | 10 | 2023 | 86 | 0.740 |
Why?
|
| Complement C4b | 4 | 2012 | 10 | 0.740 |
Why?
|
| Mice | 28 | 2025 | 11062 | 0.730 |
Why?
|
| Coinfection | 1 | 2022 | 58 | 0.730 |
Why?
|
| Protein Binding | 13 | 2018 | 1637 | 0.730 |
Why?
|
| Sialyltransferases | 3 | 2020 | 21 | 0.720 |
Why?
|
| Plants, Genetically Modified | 1 | 2020 | 23 | 0.660 |
Why?
|
| Ethanolamines | 3 | 2012 | 18 | 0.660 |
Why?
|
| Peptides | 3 | 2019 | 587 | 0.650 |
Why?
|
| Mycoplasma Infections | 2 | 2020 | 4 | 0.650 |
Why?
|
| Mycoplasma genitalium | 1 | 2020 | 3 | 0.640 |
Why?
|
| Female | 70 | 2025 | 33747 | 0.640 |
Why?
|
| Syphilis Serodiagnosis | 1 | 2020 | 4 | 0.640 |
Why?
|
| Vaginosis, Bacterial | 7 | 2006 | 15 | 0.630 |
Why?
|
| Complement Inactivator Proteins | 3 | 2008 | 8 | 0.620 |
Why?
|
| Recombinant Fusion Proteins | 6 | 2020 | 498 | 0.610 |
Why?
|
| Immune Evasion | 2 | 2025 | 71 | 0.610 |
Why?
|
| Pelvic Inflammatory Disease | 12 | 2012 | 25 | 0.590 |
Why?
|
| Mice, Inbred BALB C | 12 | 2021 | 870 | 0.590 |
Why?
|
| Lactose | 1 | 2018 | 10 | 0.570 |
Why?
|
| Oxazolidinones | 4 | 2025 | 15 | 0.560 |
Why?
|
| Isoxazoles | 4 | 2025 | 14 | 0.560 |
Why?
|
| Morpholines | 4 | 2025 | 90 | 0.540 |
Why?
|
| Virulence Factors | 2 | 2018 | 86 | 0.540 |
Why?
|
| Microbial Sensitivity Tests | 9 | 2022 | 208 | 0.530 |
Why?
|
| Lipid A | 5 | 2012 | 67 | 0.500 |
Why?
|
| Bacterial Infections | 2 | 2016 | 150 | 0.480 |
Why?
|
| Topoisomerase II Inhibitors | 1 | 2015 | 9 | 0.470 |
Why?
|
| DNA Gyrase | 1 | 2015 | 10 | 0.470 |
Why?
|
| Male | 45 | 2022 | 30787 | 0.470 |
Why?
|
| Bacteria | 2 | 2016 | 336 | 0.470 |
Why?
|
| Drug Design | 2 | 2016 | 135 | 0.460 |
Why?
|
| Polysaccharides, Bacterial | 5 | 2013 | 44 | 0.460 |
Why?
|
| Molecular Sequence Data | 18 | 2011 | 1984 | 0.460 |
Why?
|
| Immunologic Factors | 1 | 2016 | 108 | 0.450 |
Why?
|
| Genitalia, Female | 1 | 2015 | 16 | 0.450 |
Why?
|
| Complement C3b | 3 | 2007 | 18 | 0.450 |
Why?
|
| Complement Pathway, Classical | 5 | 2012 | 19 | 0.440 |
Why?
|
| China | 4 | 2021 | 174 | 0.440 |
Why?
|
| Azithromycin | 3 | 2021 | 34 | 0.430 |
Why?
|
| Amino Acid Sequence | 14 | 2011 | 1592 | 0.430 |
Why?
|
| Oligosaccharides | 5 | 2008 | 55 | 0.420 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2013 | 58 | 0.400 |
Why?
|
| Serum | 4 | 2012 | 27 | 0.390 |
Why?
|
| Species Specificity | 9 | 2011 | 341 | 0.380 |
Why?
|
| Immunization, Passive | 3 | 2021 | 96 | 0.370 |
Why?
|
| Arthritis, Infectious | 6 | 2005 | 20 | 0.370 |
Why?
|
| Immunotherapy | 3 | 2020 | 264 | 0.360 |
Why?
|
| Genital Diseases, Female | 4 | 2016 | 15 | 0.350 |
Why?
|
| Host-Pathogen Interactions | 3 | 2025 | 285 | 0.350 |
Why?
|
| Receptors, Complement | 2 | 2001 | 15 | 0.340 |
Why?
|
| Splenectomy | 1 | 2010 | 39 | 0.330 |
Why?
|
| Macrophage-1 Antigen | 1 | 2010 | 30 | 0.330 |
Why?
|
| Complement C3 | 7 | 2012 | 60 | 0.330 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 2010 | 74 | 0.320 |
Why?
|
| Glycoproteins | 2 | 2001 | 189 | 0.310 |
Why?
|
| Gene Expression Regulation, Bacterial | 3 | 2018 | 145 | 0.300 |
Why?
|
| Complement Pathway, Alternative | 4 | 2012 | 21 | 0.290 |
Why?
|
| Therapeutic Irrigation | 3 | 2003 | 17 | 0.290 |
Why?
|
| Adult | 37 | 2018 | 17234 | 0.290 |
Why?
|
| Ciprofloxacin | 2 | 2021 | 25 | 0.290 |
Why?
|
| Cytidine Monophosphate | 2 | 2020 | 9 | 0.280 |
Why?
|
| Autoimmune Diseases | 1 | 2010 | 238 | 0.280 |
Why?
|
| Properdin | 3 | 2012 | 12 | 0.260 |
Why?
|
| Polymerase Chain Reaction | 3 | 2005 | 512 | 0.260 |
Why?
|
| Galactosyltransferases | 2 | 2007 | 15 | 0.250 |
Why?
|
| Streptococcus pyogenes | 2 | 2018 | 27 | 0.250 |
Why?
|
| Heterosexuality | 3 | 2016 | 10 | 0.250 |
Why?
|
| Drug Discovery | 2 | 2017 | 95 | 0.240 |
Why?
|
| Bacterial Typing Techniques | 2 | 2005 | 11 | 0.240 |
Why?
|
| Interferons | 2 | 2025 | 73 | 0.240 |
Why?
|
| Drug Repositioning | 1 | 2025 | 10 | 0.240 |
Why?
|
| DNA, Bacterial | 3 | 2020 | 259 | 0.230 |
Why?
|
| Blood | 2 | 2005 | 31 | 0.230 |
Why?
|
| Pan troglodytes | 4 | 2011 | 33 | 0.230 |
Why?
|
| Genes, Bacterial | 3 | 2002 | 113 | 0.230 |
Why?
|
| Herpesvirus 2, Human | 1 | 2025 | 14 | 0.230 |
Why?
|
| Virulence | 4 | 2018 | 200 | 0.230 |
Why?
|
| Haemophilus influenzae | 6 | 2010 | 27 | 0.230 |
Why?
|
| Cathelicidins | 2 | 2025 | 11 | 0.220 |
Why?
|
| Endocarditis, Bacterial | 1 | 2005 | 36 | 0.220 |
Why?
|
| Diagnostic Techniques, Obstetrical and Gynecological | 1 | 2004 | 4 | 0.210 |
Why?
|
| Cervix Uteri | 4 | 2016 | 58 | 0.210 |
Why?
|
| Mass Spectrometry | 4 | 2018 | 294 | 0.200 |
Why?
|
| Interferon Type I | 1 | 2025 | 195 | 0.200 |
Why?
|
| Macrolides | 2 | 2020 | 37 | 0.190 |
Why?
|
| Bacteremia | 3 | 2011 | 92 | 0.190 |
Why?
|
| Drug Resistance, Microbial | 2 | 2015 | 46 | 0.190 |
Why?
|
| Fimbriae Proteins | 1 | 2002 | 13 | 0.190 |
Why?
|
| Immune Sera | 3 | 2005 | 35 | 0.190 |
Why?
|
| Binding Sites | 7 | 2011 | 920 | 0.180 |
Why?
|
| Adolescent | 20 | 2016 | 6287 | 0.180 |
Why?
|
| Mutation | 9 | 2019 | 2666 | 0.180 |
Why?
|
| Sexual Behavior | 2 | 2020 | 191 | 0.180 |
Why?
|
| Healthy Volunteers | 2 | 2019 | 72 | 0.180 |
Why?
|
| Gentamicins | 1 | 2021 | 24 | 0.180 |
Why?
|
| Neutrophils | 4 | 2005 | 391 | 0.170 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 8 | 2015 | 448 | 0.170 |
Why?
|
| Meningococcal Infections | 2 | 2011 | 20 | 0.170 |
Why?
|
| Immunoglobulin M | 7 | 2005 | 116 | 0.170 |
Why?
|
| Antibodies, Anti-Idiotypic | 2 | 2001 | 34 | 0.170 |
Why?
|
| United States | 16 | 2020 | 8035 | 0.170 |
Why?
|
| Antimicrobial Cationic Peptides | 3 | 2025 | 73 | 0.160 |
Why?
|
| Molecular Mimicry | 2 | 2016 | 31 | 0.160 |
Why?
|
| Amino Acid Substitution | 2 | 2011 | 237 | 0.160 |
Why?
|
| Microbial Viability | 2 | 2018 | 58 | 0.160 |
Why?
|
| Treponema pallidum | 1 | 2020 | 4 | 0.160 |
Why?
|
| Neurosyphilis | 1 | 2020 | 4 | 0.160 |
Why?
|
| RNA, Ribosomal, 23S | 1 | 2020 | 8 | 0.160 |
Why?
|
| Colony Count, Microbial | 2 | 2007 | 59 | 0.160 |
Why?
|
| Artificial Intelligence | 1 | 2023 | 209 | 0.160 |
Why?
|
| Streptococcal Infections | 3 | 2018 | 80 | 0.160 |
Why?
|
| Neuraminidase | 2 | 2016 | 43 | 0.160 |
Why?
|
| Cerebrospinal Fluid | 1 | 2020 | 29 | 0.160 |
Why?
|
| Flow Cytometry | 5 | 2016 | 662 | 0.150 |
Why?
|
| Fimbriae, Bacterial | 2 | 2019 | 19 | 0.150 |
Why?
|
| Sequence Homology, Amino Acid | 4 | 2005 | 363 | 0.150 |
Why?
|
| Complement Inactivating Agents | 2 | 2018 | 15 | 0.150 |
Why?
|
| Membrane Glycoproteins | 1 | 2002 | 664 | 0.150 |
Why?
|
| Complement C3b Inactivator Proteins | 1 | 2019 | 4 | 0.150 |
Why?
|
| Immunoglobulins | 2 | 1999 | 75 | 0.150 |
Why?
|
| Serum Bactericidal Antibody Assay | 1 | 2019 | 6 | 0.150 |
Why?
|
| Global Burden of Disease | 1 | 2019 | 13 | 0.150 |
Why?
|
| Group Processes | 1 | 2019 | 42 | 0.150 |
Why?
|
| Gene Expression Profiling | 3 | 2018 | 792 | 0.140 |
Why?
|
| Endometriosis | 1 | 1998 | 28 | 0.140 |
Why?
|
| Fluoroquinolones | 2 | 1999 | 33 | 0.140 |
Why?
|
| Urethra | 4 | 2005 | 78 | 0.140 |
Why?
|
| Public Health Surveillance | 1 | 2018 | 27 | 0.140 |
Why?
|
| Europe | 1 | 2018 | 199 | 0.140 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2020 | 249 | 0.130 |
Why?
|
| Macaca mulatta | 3 | 2008 | 260 | 0.130 |
Why?
|
| Kinetics | 2 | 2015 | 758 | 0.130 |
Why?
|
| Gene Expression | 2 | 2015 | 855 | 0.130 |
Why?
|
| Glycosphingolipids | 1 | 1996 | 9 | 0.130 |
Why?
|
| Phagocytosis | 5 | 2018 | 266 | 0.130 |
Why?
|
| Rabbits | 5 | 2001 | 334 | 0.130 |
Why?
|
| Genital Diseases, Male | 1 | 2016 | 8 | 0.130 |
Why?
|
| Uterine Cervicitis | 2 | 2002 | 3 | 0.130 |
Why?
|
| Anti-Infective Agents | 2 | 1999 | 149 | 0.130 |
Why?
|
| Cytotoxicity, Immunologic | 4 | 2003 | 140 | 0.120 |
Why?
|
| Neisseria | 1 | 2016 | 4 | 0.120 |
Why?
|
| Disease Transmission, Infectious | 1 | 2016 | 21 | 0.120 |
Why?
|
| Incidence | 2 | 2019 | 1409 | 0.120 |
Why?
|
| Gardnerella vaginalis | 3 | 2004 | 3 | 0.120 |
Why?
|
| Viral Vaccines | 1 | 2016 | 55 | 0.120 |
Why?
|
| Tetracycline | 1 | 2015 | 24 | 0.120 |
Why?
|
| In Vitro Techniques | 4 | 2001 | 494 | 0.120 |
Why?
|
| Vaccination | 3 | 2000 | 374 | 0.120 |
Why?
|
| Risk Factors | 7 | 2006 | 5395 | 0.110 |
Why?
|
| Cephalosporins | 2 | 2022 | 19 | 0.110 |
Why?
|
| Antibodies, Viral | 2 | 2016 | 324 | 0.110 |
Why?
|
| Bacterial Load | 1 | 2015 | 30 | 0.110 |
Why?
|
| Genomics | 1 | 2018 | 385 | 0.110 |
Why?
|
| beta-Lactamases | 1 | 2014 | 14 | 0.110 |
Why?
|
| Algorithms | 1 | 2020 | 1035 | 0.110 |
Why?
|
| Repressor Proteins | 2 | 2008 | 352 | 0.110 |
Why?
|
| Sensitivity and Specificity | 3 | 2005 | 1159 | 0.110 |
Why?
|
| Pregnancy | 3 | 2020 | 2361 | 0.110 |
Why?
|
| Microbiota | 1 | 2016 | 168 | 0.100 |
Why?
|
| Prevalence | 3 | 2004 | 1432 | 0.100 |
Why?
|
| Complement C4 | 3 | 2005 | 13 | 0.100 |
Why?
|
| Condylomata Acuminata | 1 | 1993 | 9 | 0.100 |
Why?
|
| Antibody Specificity | 5 | 2012 | 102 | 0.100 |
Why?
|
| Peptide Fragments | 2 | 2008 | 416 | 0.100 |
Why?
|
| Female Urogenital Diseases | 1 | 1992 | 5 | 0.100 |
Why?
|
| Male Urogenital Diseases | 1 | 1992 | 4 | 0.100 |
Why?
|
| Th1 Cells | 1 | 2013 | 168 | 0.100 |
Why?
|
| Fluorescent Antibody Technique | 2 | 1992 | 236 | 0.090 |
Why?
|
| Mice, Inbred C57BL | 4 | 2025 | 3452 | 0.090 |
Why?
|
| Base Sequence | 4 | 2005 | 1327 | 0.090 |
Why?
|
| Protein Structure, Tertiary | 2 | 2011 | 676 | 0.090 |
Why?
|
| Surveys and Questionnaires | 2 | 2018 | 2754 | 0.090 |
Why?
|
| Transcriptome | 1 | 2015 | 397 | 0.090 |
Why?
|
| beta-Glucans | 1 | 2012 | 57 | 0.090 |
Why?
|
| Histocompatibility Antigens | 1 | 2012 | 107 | 0.090 |
Why?
|
| Lectins, C-Type | 1 | 2012 | 90 | 0.090 |
Why?
|
| Fungi | 1 | 2011 | 61 | 0.090 |
Why?
|
| Meningococcal Vaccines | 1 | 2011 | 19 | 0.090 |
Why?
|
| Mice, Knockout | 3 | 2025 | 2148 | 0.080 |
Why?
|
| Oligopeptides | 1 | 2011 | 135 | 0.080 |
Why?
|
| Neisseria meningitidis, Serogroup A | 1 | 2010 | 2 | 0.080 |
Why?
|
| Neisseria meningitidis, Serogroup Y | 1 | 2010 | 2 | 0.080 |
Why?
|
| Neisseria meningitidis, Serogroup W-135 | 1 | 2010 | 3 | 0.080 |
Why?
|
| Neisseria meningitidis, Serogroup B | 1 | 2010 | 6 | 0.080 |
Why?
|
| Neisseria meningitidis, Serogroup C | 1 | 2010 | 4 | 0.080 |
Why?
|
| Streptococcus pneumoniae | 1 | 2010 | 67 | 0.080 |
Why?
|
| Cricetulus | 1 | 2010 | 101 | 0.080 |
Why?
|
| Arginine | 1 | 2011 | 136 | 0.080 |
Why?
|
| CHO Cells | 1 | 2010 | 189 | 0.080 |
Why?
|
| Cell Separation | 1 | 2010 | 147 | 0.080 |
Why?
|
| Heparin | 1 | 2011 | 118 | 0.080 |
Why?
|
| Escherichia coli | 2 | 1992 | 707 | 0.080 |
Why?
|
| Respiratory Tract Infections | 1 | 2010 | 86 | 0.080 |
Why?
|
| Polysaccharides | 1 | 2011 | 153 | 0.080 |
Why?
|
| Cricetinae | 1 | 2010 | 369 | 0.080 |
Why?
|
| Cloning, Molecular | 4 | 2002 | 384 | 0.080 |
Why?
|
| Naphthyridines | 1 | 1999 | 7 | 0.080 |
Why?
|
| Doxycycline | 1 | 1999 | 47 | 0.080 |
Why?
|
| Gram-Negative Bacteria | 2 | 2005 | 56 | 0.080 |
Why?
|
| NADH, NADPH Oxidoreductases | 1 | 1989 | 18 | 0.080 |
Why?
|
| Chlamydia | 1 | 1989 | 11 | 0.070 |
Why?
|
| Endotoxins | 3 | 1995 | 81 | 0.070 |
Why?
|
| Transfection | 1 | 2010 | 701 | 0.070 |
Why?
|
| Regulon | 1 | 2008 | 6 | 0.070 |
Why?
|
| Papio | 1 | 2008 | 21 | 0.070 |
Why?
|
| Child, Preschool | 4 | 2010 | 2050 | 0.070 |
Why?
|
| Risk-Taking | 1 | 2009 | 160 | 0.070 |
Why?
|
| Blotting, Western | 3 | 2015 | 610 | 0.070 |
Why?
|
| Cefotaxime | 1 | 1997 | 4 | 0.070 |
Why?
|
| Typhoid Fever | 3 | 1977 | 21 | 0.070 |
Why?
|
| Amino Acid Motifs | 1 | 2008 | 156 | 0.070 |
Why?
|
| Quinolones | 1 | 1997 | 25 | 0.070 |
Why?
|
| Chemotaxis, Leukocyte | 1 | 1987 | 61 | 0.060 |
Why?
|
| HIV Infections | 3 | 2004 | 951 | 0.060 |
Why?
|
| Protein Isoforms | 1 | 2007 | 202 | 0.060 |
Why?
|
| Models, Molecular | 1 | 2011 | 1158 | 0.060 |
Why?
|
| Piperazines | 1 | 1997 | 86 | 0.060 |
Why?
|
| Child | 7 | 2010 | 4597 | 0.060 |
Why?
|
| Binding, Competitive | 4 | 2011 | 97 | 0.060 |
Why?
|
| Cells, Cultured | 4 | 2019 | 2184 | 0.060 |
Why?
|
| Epithelial Cells | 2 | 2008 | 416 | 0.060 |
Why?
|
| Synovial Membrane | 2 | 1984 | 21 | 0.060 |
Why?
|
| Vitronectin | 1 | 2006 | 7 | 0.060 |
Why?
|
| Skin Diseases, Bacterial | 1 | 2005 | 8 | 0.060 |
Why?
|
| Defensins | 1 | 2005 | 4 | 0.060 |
Why?
|
| Leukocytes, Mononuclear | 2 | 1996 | 245 | 0.060 |
Why?
|
| Transferrin-Binding Protein A | 1 | 2005 | 1 | 0.060 |
Why?
|
| Transferrin-Binding Protein B | 1 | 2005 | 1 | 0.060 |
Why?
|
| Molecular Weight | 3 | 2003 | 193 | 0.060 |
Why?
|
| Carrier Proteins | 2 | 2018 | 718 | 0.060 |
Why?
|
| Haemophilus ducreyi | 1 | 2005 | 2 | 0.060 |
Why?
|
| Cross Reactions | 3 | 1996 | 136 | 0.060 |
Why?
|
| Gram-Positive Bacteria | 1 | 2005 | 35 | 0.060 |
Why?
|
| Genotype | 2 | 2018 | 675 | 0.060 |
Why?
|
| DNA Probes | 1 | 2005 | 33 | 0.060 |
Why?
|
| DNA, Ribosomal | 1 | 2005 | 31 | 0.060 |
Why?
|
| HIV Seroprevalence | 3 | 1992 | 7 | 0.060 |
Why?
|
| Receptor, Interferon alpha-beta | 1 | 2025 | 52 | 0.060 |
Why?
|
| Vaginal Douching | 1 | 2005 | 3 | 0.060 |
Why?
|
| Heart Valves | 1 | 2005 | 26 | 0.060 |
Why?
|
| Nucleic Acid Hybridization | 1 | 2005 | 99 | 0.060 |
Why?
|
| Sequence Alignment | 1 | 2005 | 300 | 0.060 |
Why?
|
| Middle Aged | 9 | 2014 | 18108 | 0.060 |
Why?
|
| Otitis Media | 2 | 2000 | 12 | 0.060 |
Why?
|
| Bacterial Adhesion | 2 | 2019 | 64 | 0.060 |
Why?
|
| Drug Synergism | 2 | 2021 | 143 | 0.050 |
Why?
|
| RNA, Bacterial | 1 | 2005 | 73 | 0.050 |
Why?
|
| Sex Factors | 4 | 2018 | 987 | 0.050 |
Why?
|
| Contraceptives, Oral | 2 | 1997 | 23 | 0.050 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2005 | 105 | 0.050 |
Why?
|
| Genetic Variation | 2 | 2005 | 397 | 0.050 |
Why?
|
| Salmonella Infections | 2 | 1976 | 42 | 0.050 |
Why?
|
| HIV-2 | 1 | 2004 | 23 | 0.050 |
Why?
|
| Lectins | 2 | 2002 | 43 | 0.050 |
Why?
|
| Immunoglobulin Fab Fragments | 3 | 2011 | 33 | 0.050 |
Why?
|
| Aged | 6 | 2014 | 14838 | 0.050 |
Why?
|
| Boston | 3 | 2003 | 258 | 0.050 |
Why?
|
| California | 1 | 2004 | 173 | 0.050 |
Why?
|
| Sepsis | 2 | 1978 | 291 | 0.050 |
Why?
|
| Gram-Negative Anaerobic Bacteria | 1 | 2003 | 1 | 0.050 |
Why?
|
| Mobiluncus | 1 | 2003 | 1 | 0.050 |
Why?
|
| Sexually Transmitted Diseases, Bacterial | 1 | 2003 | 2 | 0.050 |
Why?
|
| Mycoplasma hominis | 1 | 2003 | 2 | 0.050 |
Why?
|
| Amides | 1 | 2003 | 60 | 0.050 |
Why?
|
| Time Factors | 4 | 2005 | 3744 | 0.050 |
Why?
|
| Syphilis, Cardiovascular | 1 | 2002 | 1 | 0.050 |
Why?
|
| Aortitis | 1 | 2002 | 5 | 0.050 |
Why?
|
| Dysentery, Bacillary | 3 | 1980 | 13 | 0.050 |
Why?
|
| Antibody Formation | 2 | 1986 | 110 | 0.050 |
Why?
|
| Lactobacillus | 1 | 2002 | 7 | 0.050 |
Why?
|
| Urinary Tract Infections | 1 | 1984 | 97 | 0.050 |
Why?
|
| Poly G | 1 | 2002 | 2 | 0.050 |
Why?
|
| Disease Susceptibility | 1 | 2003 | 168 | 0.050 |
Why?
|
| Complement C1 Inactivator Proteins | 1 | 2002 | 3 | 0.050 |
Why?
|
| alpha-Macroglobulins | 1 | 2002 | 3 | 0.050 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 2002 | 111 | 0.050 |
Why?
|
| Pneumococcal Infections | 2 | 1981 | 39 | 0.050 |
Why?
|
| Cell Division | 1 | 2023 | 448 | 0.050 |
Why?
|
| Mannans | 1 | 2002 | 22 | 0.050 |
Why?
|
| Mice, Transgenic | 2 | 2019 | 1281 | 0.050 |
Why?
|
| Conserved Sequence | 2 | 1999 | 173 | 0.050 |
Why?
|
| Depression | 1 | 2009 | 890 | 0.050 |
Why?
|
| Education | 2 | 2016 | 67 | 0.040 |
Why?
|
| Drug Therapy, Combination | 2 | 2021 | 461 | 0.040 |
Why?
|
| Iron | 2 | 2015 | 151 | 0.040 |
Why?
|
| Disease Outbreaks | 3 | 1977 | 111 | 0.040 |
Why?
|
| Protein S | 1 | 2001 | 2 | 0.040 |
Why?
|
| Cell Line | 2 | 2006 | 2036 | 0.040 |
Why?
|
| Neuraminic Acids | 1 | 2020 | 3 | 0.040 |
Why?
|
| Cytidine Monophosphate N-Acetylneuraminic Acid | 2 | 2015 | 7 | 0.040 |
Why?
|
| Haemophilus Vaccines | 1 | 2000 | 4 | 0.040 |
Why?
|
| Antigenic Variation | 1 | 2000 | 7 | 0.040 |
Why?
|
| Membrane Proteins | 2 | 1986 | 921 | 0.040 |
Why?
|
| Immunization | 1 | 2001 | 136 | 0.040 |
Why?
|
| Socioeconomic Factors | 1 | 2003 | 796 | 0.040 |
Why?
|
| Carbohydrates | 1 | 1999 | 41 | 0.040 |
Why?
|
| Young Adult | 3 | 2016 | 4771 | 0.040 |
Why?
|
| Inpatients | 1 | 1992 | 310 | 0.040 |
Why?
|
| Topoisomerase Inhibitors | 1 | 2019 | 4 | 0.040 |
Why?
|
| Prognosis | 1 | 2004 | 1775 | 0.040 |
Why?
|
| Health Behavior | 1 | 2003 | 482 | 0.040 |
Why?
|
| Complement Factor B | 1 | 1999 | 11 | 0.040 |
Why?
|
| World Health Organization | 1 | 2019 | 35 | 0.040 |
Why?
|
| Logistic Models | 1 | 2002 | 1270 | 0.040 |
Why?
|
| Epidemiological Monitoring | 1 | 2019 | 32 | 0.040 |
Why?
|
| Molecular Structure | 2 | 1997 | 314 | 0.040 |
Why?
|
| Antimicrobial Stewardship | 1 | 2019 | 18 | 0.040 |
Why?
|
| Gene Amplification | 1 | 1998 | 27 | 0.040 |
Why?
|
| Immunity, Humoral | 1 | 2019 | 39 | 0.040 |
Why?
|
| Triazoles | 1 | 2019 | 63 | 0.040 |
Why?
|
| Glucosyltransferases | 1 | 1998 | 15 | 0.040 |
Why?
|
| Sequence Analysis | 1 | 2018 | 12 | 0.040 |
Why?
|
| Contraceptive Agents, Female | 1 | 1998 | 24 | 0.040 |
Why?
|
| Cities | 1 | 2018 | 32 | 0.030 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 3 | 2008 | 89 | 0.030 |
Why?
|
| Massachusetts | 1 | 2004 | 2137 | 0.030 |
Why?
|
| Abdominal Pain | 1 | 1998 | 103 | 0.030 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 1 | 1998 | 85 | 0.030 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2003 | 768 | 0.030 |
Why?
|
| Salmonella | 2 | 1987 | 45 | 0.030 |
Why?
|
| Endometritis | 1 | 1997 | 4 | 0.030 |
Why?
|
| Blood Group Antigens | 1 | 1996 | 6 | 0.030 |
Why?
|
| Sequence Analysis, RNA | 1 | 2018 | 181 | 0.030 |
Why?
|
| Phenotype | 1 | 2001 | 1233 | 0.030 |
Why?
|
| Public Health | 1 | 2019 | 186 | 0.030 |
Why?
|
| Coitus | 1 | 2016 | 15 | 0.030 |
Why?
|
| Plant Lectins | 1 | 1996 | 7 | 0.030 |
Why?
|
| Nucleic Acid Amplification Techniques | 1 | 2016 | 24 | 0.030 |
Why?
|
| Glycosyltransferases | 1 | 1996 | 9 | 0.030 |
Why?
|
| Phylogeny | 1 | 2018 | 384 | 0.030 |
Why?
|
| National Institute of Allergy and Infectious Diseases (U.S.) | 1 | 2016 | 4 | 0.030 |
Why?
|
| Sexual Partners | 1 | 2016 | 75 | 0.030 |
Why?
|
| Enteritis | 1 | 1976 | 13 | 0.030 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2016 | 95 | 0.030 |
Why?
|
| Counseling | 2 | 1993 | 374 | 0.030 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 1 | 1995 | 20 | 0.030 |
Why?
|
| Opsonin Proteins | 2 | 2002 | 32 | 0.030 |
Why?
|
| Bacteriological Techniques | 2 | 1994 | 29 | 0.030 |
Why?
|
| T-Lymphocytes | 1 | 1999 | 1003 | 0.030 |
Why?
|
| Vaginal Smears | 2 | 2006 | 59 | 0.030 |
Why?
|
| Haemophilus Infections | 2 | 1985 | 13 | 0.030 |
Why?
|
| Cross Infection | 1 | 1976 | 165 | 0.030 |
Why?
|
| Antigens, CD | 1 | 1995 | 343 | 0.030 |
Why?
|
| Carbohydrate Sequence | 3 | 1999 | 21 | 0.030 |
Why?
|
| Indicators and Reagents | 1 | 1994 | 53 | 0.030 |
Why?
|
| Binding Sites, Antibody | 2 | 2002 | 21 | 0.030 |
Why?
|
| Interviews as Topic | 2 | 2009 | 529 | 0.030 |
Why?
|
| Biomedical Research | 1 | 2016 | 270 | 0.020 |
Why?
|
| Multiple Myeloma | 1 | 1978 | 364 | 0.020 |
Why?
|
| Animal Feed | 1 | 1973 | 15 | 0.020 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2012 | 633 | 0.020 |
Why?
|
| Food Contamination | 1 | 1973 | 22 | 0.020 |
Why?
|
| Keratolytic Agents | 1 | 1993 | 2 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2016 | 460 | 0.020 |
Why?
|
| Penile Diseases | 1 | 1993 | 7 | 0.020 |
Why?
|
| Tenosynovitis | 2 | 1983 | 6 | 0.020 |
Why?
|
| Immunoassay | 2 | 1987 | 71 | 0.020 |
Why?
|
| Papillomaviridae | 1 | 1993 | 59 | 0.020 |
Why?
|
| Elapid Venoms | 1 | 1992 | 2 | 0.020 |
Why?
|
| Antibodies, Blocking | 1 | 2012 | 38 | 0.020 |
Why?
|
| Ovalbumin | 1 | 2012 | 109 | 0.020 |
Why?
|
| Recombinant Proteins | 2 | 2007 | 710 | 0.020 |
Why?
|
| Liposomes | 1 | 1992 | 116 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 1993 | 371 | 0.020 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 1992 | 70 | 0.020 |
Why?
|
| DNA, Viral | 1 | 1993 | 231 | 0.020 |
Why?
|
| Cell Membrane | 2 | 1989 | 507 | 0.020 |
Why?
|
| Zymosan | 1 | 2011 | 25 | 0.020 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 2 | 1985 | 185 | 0.020 |
Why?
|
| Immunoblotting | 2 | 2005 | 203 | 0.020 |
Why?
|
| Vaccines, Conjugate | 1 | 2011 | 18 | 0.020 |
Why?
|
| Ligands | 1 | 2012 | 412 | 0.020 |
Why?
|
| Animals, Genetically Modified | 1 | 2011 | 310 | 0.020 |
Why?
|
| Dermatitis | 2 | 1981 | 24 | 0.020 |
Why?
|
| Complement C3 Convertase, Alternative Pathway | 1 | 2010 | 5 | 0.020 |
Why?
|
| Enzyme Stability | 1 | 2010 | 47 | 0.020 |
Why?
|
| Macrophages | 2 | 2012 | 1047 | 0.020 |
Why?
|
| Research | 1 | 1991 | 194 | 0.020 |
Why?
|
| Immunity, Innate | 2 | 2011 | 827 | 0.020 |
Why?
|
| Microscopy, Electron | 1 | 1990 | 253 | 0.020 |
Why?
|
| Adjuvants, Immunologic | 1 | 2011 | 234 | 0.020 |
Why?
|
| Follow-Up Studies | 2 | 2005 | 2483 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2016 | 2676 | 0.020 |
Why?
|
| N-Formylmethionine Leucyl-Phenylalanine | 1 | 1989 | 19 | 0.020 |
Why?
|
| Free Radicals | 1 | 1989 | 19 | 0.020 |
Why?
|
| Superoxides | 1 | 1989 | 73 | 0.020 |
Why?
|
| Infant | 4 | 1981 | 1685 | 0.020 |
Why?
|
| Dendritic Cells | 1 | 2012 | 532 | 0.020 |
Why?
|
| Drug Contamination | 1 | 1989 | 11 | 0.020 |
Why?
|
| Cytoplasmic Granules | 1 | 1989 | 53 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2011 | 850 | 0.020 |
Why?
|
| Genes | 1 | 1989 | 90 | 0.020 |
Why?
|
| Unsafe Sex | 1 | 2009 | 27 | 0.020 |
Why?
|
| Polymyxin B | 1 | 2008 | 11 | 0.020 |
Why?
|
| NADPH Oxidases | 1 | 1989 | 71 | 0.020 |
Why?
|
| Diagnostic Errors | 2 | 2002 | 104 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2020 | 5755 | 0.020 |
Why?
|
| Serotyping | 2 | 2005 | 52 | 0.020 |
Why?
|
| Cohort Studies | 2 | 2005 | 2607 | 0.020 |
Why?
|
| Operator Regions, Genetic | 1 | 2008 | 6 | 0.020 |
Why?
|
| Oxygen Consumption | 1 | 1989 | 213 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 1990 | 902 | 0.020 |
Why?
|
| Mucous Membrane | 1 | 2008 | 26 | 0.020 |
Why?
|
| Rats | 1 | 2011 | 1994 | 0.020 |
Why?
|
| AIDS Serodiagnosis | 2 | 1992 | 19 | 0.020 |
Why?
|
| Cefixime | 1 | 1997 | 1 | 0.020 |
Why?
|
| beta-Lactam Resistance | 1 | 1997 | 4 | 0.020 |
Why?
|
| Penicillin Resistance | 1 | 1997 | 11 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 1999 | 739 | 0.020 |
Why?
|
| Administration, Oral | 2 | 1997 | 370 | 0.020 |
Why?
|
| Prospective Studies | 2 | 2005 | 3303 | 0.020 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2007 | 251 | 0.020 |
Why?
|
| Glycolipids | 1 | 1986 | 44 | 0.020 |
Why?
|
| Green Fluorescent Proteins | 1 | 2008 | 374 | 0.020 |
Why?
|
| Complement C9 | 1 | 1985 | 4 | 0.010 |
Why?
|
| Antigen-Antibody Complex | 1 | 1985 | 52 | 0.010 |
Why?
|
| Calcium | 1 | 1989 | 583 | 0.010 |
Why?
|
| Alleles | 1 | 2007 | 454 | 0.010 |
Why?
|
| Complement C1q | 1 | 2005 | 17 | 0.010 |
Why?
|
| Travel | 2 | 1977 | 42 | 0.010 |
Why?
|
| Otitis Media with Effusion | 1 | 1985 | 8 | 0.010 |
Why?
|
| Promoter Regions, Genetic | 1 | 2008 | 682 | 0.010 |
Why?
|
| Chinchilla | 2 | 2000 | 5 | 0.010 |
Why?
|
| DNA Primers | 1 | 2005 | 300 | 0.010 |
Why?
|
| Peptide Hydrolases | 1 | 2005 | 79 | 0.010 |
Why?
|
| Confidence Intervals | 1 | 2005 | 238 | 0.010 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 1999 | 604 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2011 | 1633 | 0.010 |
Why?
|
| Cluster Analysis | 1 | 2005 | 260 | 0.010 |
Why?
|
| Antigens, Surface | 1 | 1985 | 200 | 0.010 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2004 | 92 | 0.010 |
Why?
|
| Trichomonas Vaginitis | 1 | 1984 | 7 | 0.010 |
Why?
|
| Candidiasis, Vulvovaginal | 1 | 1984 | 8 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2005 | 543 | 0.010 |
Why?
|
| Vaginitis | 1 | 1984 | 6 | 0.010 |
Why?
|
| Cystitis | 1 | 1984 | 10 | 0.010 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2004 | 94 | 0.010 |
Why?
|
| Injections, Intra-Articular | 1 | 1984 | 52 | 0.010 |
Why?
|
| Synovitis | 1 | 1984 | 30 | 0.010 |
Why?
|
| Knee | 1 | 1984 | 40 | 0.010 |
Why?
|
| Skin Diseases, Infectious | 1 | 1983 | 12 | 0.010 |
Why?
|
| Sequence Analysis, DNA | 1 | 2005 | 417 | 0.010 |
Why?
|
| Viral Load | 1 | 2004 | 228 | 0.010 |
Why?
|
| Abscess | 1 | 1984 | 78 | 0.010 |
Why?
|
| Odds Ratio | 1 | 2005 | 759 | 0.010 |
Why?
|
| South Carolina | 1 | 2003 | 15 | 0.010 |
Why?
|
| Colorado | 1 | 2003 | 21 | 0.010 |
Why?
|
| Cell Wall | 1 | 1984 | 120 | 0.010 |
Why?
|
| Alabama | 1 | 2003 | 85 | 0.010 |
Why?
|
| Pennsylvania | 1 | 2003 | 65 | 0.010 |
Why?
|
| Hospitals, Special | 1 | 1992 | 9 | 0.010 |
Why?
|
| Serum Bactericidal Test | 1 | 2002 | 2 | 0.010 |
Why?
|
| Collectins | 1 | 2002 | 4 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 2006 | 1273 | 0.010 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 2002 | 50 | 0.010 |
Why?
|
| Neoplasms | 1 | 1993 | 1359 | 0.010 |
Why?
|
| Escherichia coli Infections | 1 | 1983 | 88 | 0.010 |
Why?
|
| Cell Survival | 1 | 1984 | 579 | 0.010 |
Why?
|
| Infant, Newborn | 2 | 1977 | 1412 | 0.010 |
Why?
|
| Comorbidity | 1 | 2005 | 1115 | 0.010 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 1992 | 131 | 0.010 |
Why?
|
| Staphylococcal Infections | 1 | 1983 | 135 | 0.010 |
Why?
|
| Self Care | 1 | 2003 | 213 | 0.010 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2002 | 186 | 0.010 |
Why?
|
| Health Education | 1 | 2003 | 191 | 0.010 |
Why?
|
| Pericarditis | 1 | 1981 | 10 | 0.010 |
Why?
|
| Patient Selection | 1 | 2003 | 483 | 0.010 |
Why?
|
| Ear, Middle | 1 | 2000 | 8 | 0.010 |
Why?
|
| Transformation, Bacterial | 1 | 2000 | 12 | 0.010 |
Why?
|
| Diphenoxylate | 1 | 1980 | 1 | 0.010 |
Why?
|
| Shigella dysenteriae | 1 | 1980 | 1 | 0.010 |
Why?
|
| Knee Joint | 1 | 1983 | 310 | 0.010 |
Why?
|
| Atropine | 1 | 1980 | 13 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 1992 | 929 | 0.010 |
Why?
|
| Age Factors | 2 | 1990 | 1580 | 0.010 |
Why?
|
| Mutagenesis, Insertional | 1 | 2000 | 93 | 0.010 |
Why?
|
| Women's Health | 1 | 2003 | 374 | 0.010 |
Why?
|
| Mexico | 2 | 1977 | 38 | 0.010 |
Why?
|
| Drug Combinations | 1 | 1980 | 166 | 0.010 |
Why?
|
| Immunity, Mucosal | 1 | 1999 | 54 | 0.010 |
Why?
|
| Colitis, Ulcerative | 1 | 1980 | 77 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2005 | 1573 | 0.010 |
Why?
|
| Interleukin-12 | 1 | 1999 | 127 | 0.010 |
Why?
|
| Integrins | 1 | 1999 | 109 | 0.010 |
Why?
|
| Interleukin-2 | 1 | 1999 | 167 | 0.010 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 1999 | 112 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2003 | 1689 | 0.010 |
Why?
|
| DNA, Recombinant | 1 | 1998 | 47 | 0.010 |
Why?
|
| Interleukin-10 | 1 | 1999 | 163 | 0.010 |
Why?
|
| Open Reading Frames | 1 | 1998 | 84 | 0.010 |
Why?
|
| Feces | 2 | 1976 | 118 | 0.010 |
Why?
|
| Chromatography, Gel | 1 | 1977 | 63 | 0.010 |
Why?
|
| Carrier State | 1 | 1977 | 20 | 0.010 |
Why?
|
| Salmonella typhi | 1 | 1977 | 19 | 0.010 |
Why?
|
| Spectrometry, Mass, Secondary Ion | 1 | 1997 | 7 | 0.010 |
Why?
|
| Disaccharides | 1 | 1997 | 11 | 0.010 |
Why?
|
| Chloramphenicol | 1 | 1977 | 6 | 0.010 |
Why?
|
| Interferon-gamma | 1 | 1999 | 569 | 0.010 |
Why?
|
| Epidemiologic Methods | 1 | 1977 | 67 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 1980 | 989 | 0.010 |
Why?
|
| Endometrium | 1 | 1997 | 31 | 0.010 |
Why?
|
| Lymphocyte Activation | 1 | 1999 | 750 | 0.010 |
Why?
|
| Monosaccharides | 1 | 1996 | 7 | 0.010 |
Why?
|
| Blotting, Southern | 1 | 1996 | 56 | 0.010 |
Why?
|
| Restriction Mapping | 1 | 1996 | 49 | 0.010 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 1997 | 221 | 0.010 |
Why?
|
| Exudates and Transudates | 1 | 1996 | 12 | 0.010 |
Why?
|
| Microscopy, Immunoelectron | 1 | 1996 | 31 | 0.010 |
Why?
|
| Chromatography, Affinity | 2 | 1986 | 50 | 0.010 |
Why?
|
| Vacuoles | 1 | 1996 | 31 | 0.010 |
Why?
|
| Fatty Acids | 1 | 1997 | 196 | 0.010 |
Why?
|
| Epithelium | 1 | 1996 | 100 | 0.010 |
Why?
|
| Puerto Rico | 1 | 1976 | 137 | 0.010 |
Why?
|
| Membrane Fusion | 1 | 1996 | 68 | 0.010 |
Why?
|
| Microscopy, Confocal | 1 | 1996 | 243 | 0.010 |
Why?
|
| Lipopolysaccharide Receptors | 1 | 1995 | 144 | 0.010 |
Why?
|
| Macrophage Activation | 1 | 1995 | 116 | 0.010 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 1999 | 654 | 0.010 |
Why?
|
| Risk | 2 | 1986 | 377 | 0.010 |
Why?
|
| Shigella sonnei | 1 | 1974 | 3 | 0.010 |
Why?
|
| Vaccines, Attenuated | 1 | 1974 | 35 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 1997 | 1141 | 0.010 |
Why?
|
| NF-kappa B | 1 | 1995 | 435 | 0.010 |
Why?
|
| Food Preservation | 1 | 1973 | 18 | 0.010 |
Why?
|
| Intestinal Diseases | 1 | 1973 | 36 | 0.010 |
Why?
|
| Food Microbiology | 1 | 1973 | 43 | 0.010 |
Why?
|
| Family Planning Services | 1 | 1992 | 21 | 0.010 |
Why?
|
| Fetal Blood | 1 | 1992 | 73 | 0.010 |
Why?
|
| Labor, Obstetric | 1 | 1992 | 35 | 0.010 |
Why?
|
| Abortion, Induced | 1 | 1992 | 29 | 0.010 |
Why?
|
| Substance Abuse, Intravenous | 1 | 1992 | 83 | 0.010 |
Why?
|
| Acetic Acid | 1 | 1987 | 10 | 0.000 |
Why?
|
| Acetates | 1 | 1987 | 29 | 0.000 |
Why?
|
| Hydrolysis | 1 | 1987 | 147 | 0.000 |
Why?
|
| Immunosorbent Techniques | 1 | 1985 | 9 | 0.000 |
Why?
|
| Body Fluids | 1 | 1985 | 20 | 0.000 |
Why?
|
| Menstrual Cycle | 1 | 1985 | 83 | 0.000 |
Why?
|
| Signal Transduction | 1 | 1995 | 3140 | 0.000 |
Why?
|
| Immunoglobulin A | 1 | 1985 | 102 | 0.000 |
Why?
|
| Pain | 1 | 1983 | 398 | 0.000 |
Why?
|
| Epididymitis | 1 | 1977 | 2 | 0.000 |
Why?
|
| Immunologic Techniques | 1 | 1977 | 11 | 0.000 |
Why?
|
| Convalescence | 1 | 1977 | 18 | 0.000 |
Why?
|
| Extrachromosomal Inheritance | 1 | 1974 | 1 | 0.000 |
Why?
|
| Genetics, Microbial | 1 | 1974 | 10 | 0.000 |
Why?
|
| Shigella flexneri | 1 | 1974 | 18 | 0.000 |
Why?
|
| Dysentery, Amebic | 1 | 1973 | 1 | 0.000 |
Why?
|
| Gastroenteritis | 1 | 1973 | 15 | 0.000 |
Why?
|
| Hospitals, Psychiatric | 1 | 1974 | 56 | 0.000 |
Why?
|
| New York | 1 | 1974 | 144 | 0.000 |
Why?
|